We are a team of academic and industry health economists with experience in several large-scale projects worldwide. For the last 15 years, GearEconomics is involved in many research projects, including outcomes research, biostatistics, and clinical research, employing all types of economic modeling and in various diseases and medical specialties, such as cardiology, oncology, assisted reproductive technology, diabetes mellitus, multiple myeloma, psoriasis, rheumatoid arthritis, and others, including a large number of clinical trials.  

We also focus on Health Economics projects in the field of Personalised Medicine and Pharmacogenomics (PGx) and deliver HTA work by participating in collaborative grants, funded by the European Commission. A representative example is the Horizon 2020 U-PGx project (Ubiquitous Pharmacogenomics;  www.upgx.eu), aiming to address major challenges and obstacles for the implementation of pharmacogenomic testing in patient care. U-PGx will investigate if the pre-emptive genotyping approach using an entire panel of important PGx markers is cost-effective. The new model of personalized medicine through pre-emptive PGx-testing is currently being conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia). It is a unique project, since it does not only involve a very large number of patients, the largest among the very few similar projects worldwide, but it also addresses cost-effectiveness of the pre-emptive genotyping approach as a secondary outcome.